Immunologic and Prognostic Factors Associated with Overall Survival Employing a Poxviral-based PSA Vaccine in Metastatic Castrate-resistant Prostate Cancer

A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p=0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gulley, James L., Arlen, Philip M., Madan, Ravi A., Tsang, Kwong-Yok, Pazdur, Mary P., Skarupa, Lisa, Jones, Jacquin L., Poole, Diane J., Higgins, Jack P., Hodge, James W., Cereda, Vittore, Vergati, Matteo, Steinberg, Seth M., Halabi, Susan, Jones, Elizabeth, Chen, Clara, Parnes, Howard, Wright, John J., Dahut, William L., Schlom, Jeffrey
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2832083/
https://ncbi.nlm.nih.gov/pubmed/19890632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-009-0782-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados